Previous 10 | Next 10 |
Windtree to Present at the H.C. Wainwright Global Life Sciences Conference PR Newswire WARRINGTON, Pa. , March 8, 2021 /PRNewswire/ -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late...
Gainers: Ovid Therapeutics (OVID) +48%, KemPharm (KMPH) +46%, Ocugen (OCGN) +34%, Asensus Surgical (TRXC) +32%, Heat Biologics (HTBX) +16%.Losers: Vir Biotechnology (VIR) -29%, NanoViricides (NNVC) -16%, ASLAN Pharmaceutica...
NanoViricides (NNVC) +112% on effectiveness of COVID-19 drug candidates in cell culture studies.Communications Systems (JCS) +38% after entering merger agreement with Pineapple Energy.STRATA Skin Sciences (SSKN) +30% on announcing CEO Transition.CHF Solutions (CHFS) +25%.AgeX T...
Windtree Announces Issuance of New U.S. Patent Covering Technology on Its Redesigned AEROSURF® Device New patent covers updated aerosol delivery system and design until 2039 PR Newswire WARRINGTON, Pa. , Feb. 16, 2021 /PRNewswire/ -- Windtree Therapeutic...
Windtree Strengthens Its Board by Appointing Three New Directors Company welcomes Dr. Evan Loh, Ms. Leslie Williams and Dr. Rob Scott, seasoned executives with deep cardiovascular development and commercial experience PR Newswire WARRINGTON, Pa. , Feb. 4, 2021 ...
Windtree Appoints Dr. Joseph Soffer to Lead Cardiovascular Clinical Development PR Newswire WARRINGTON, Pa. , Feb. 1, 2021 /PRNewswire/ -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-...
Biotechnology and medical device company Windtree Therapeutics (WINT) has dosed the first patient in its Phase 2 trial studying lucinactant in acute lung injury in adults with COVID-19 associated lung injury and acute respiratory distress syndrome ((ARDS)).Lucinactant is a synthetic KL4 surfa...
Windtree Announces First Patient Dosed in its Phase 2 Clinical Trial Studying KL4 Surfactant in Acute Lung Injury in Adults with COVID-19 The Phase 2 study will evaluate key physiological measures and is expected to be completed in 3-6 months PR Newswire WARRINGTON...
Windtree Therapeutics (WINT): Q3 GAAP EPS of -$0.54.Press Release For further details see: Windtree Therapeutics reports Q3 results
Windtree Therapeutics Reports Third Quarter 2020 Financial Results and Provides Key Business Updates PR Newswire WARRINGTON, Pa., Nov. 16, 2020 WARRINGTON, Pa. , Nov. 16, 2020 /PRNewswire/ -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology ...
News, Short Squeeze, Breakout and More Instantly...
Windtree Therapeutics Inc. Company Name:
WINT Stock Symbol:
OTCMKTS Market:
Windtree Therapeutics Inc. Website:
$12.9 Million Transaction Includes Approximately $3.4 Million of New Funding and a $9.5 Million Full Cancellation of Outstanding Senior Notes and Extinguishment of Series B Preferred Shares The Company Also Established a $35 Million Equity Line of Credit WA...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...
Gelesis Holdings, Inc. (GLSHQ) is expected to report for Q1 2024 EVmo Inc (YAYO) is expected to report for Q1 2024 Chiba Bank Ltd. ADR (CHBAY) is expected to report for Q4 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ToughBuilt Industries Inc. (TBLT) is expecte...